uterine transfusions, however, fetomaternal haemorrhage may enhance maternal sensitisation. Not only might the disease be worsened in a subsequent pregnancy but also in the present pregnancy the rate of fall in fetal packed cell volume might be accelerated by an increase in maternal antibody titre, particularly after the first transfusion, when fetal erythropoiesis is generally not yet suppressed.
Precisely estimating the volume of fetomaternal haemorrhage is difficult. In patients undergoing intrauterine transfusions the Kleihauer-Betke test cannot be used because donor red cells cannot be identified in the maternal circulation. The increase in maternal a fetoprotein concentration can give a reliable estimate if fetal a fetoprotein concentration is also assayed. Possible sources of error are the estimated maternal blood volume, which cannot practically be assessed in each patient, and passage of a fetoprotein into the maternal circulation from fluids other than fetal blood, such as the amniotic fluid. This second possibility is unlikely as fetomaternal haemorrhage occurred most commonly when the site of sampling and transfusion was the placental cord insertion with an anterior placenta-that is, when the needle entered directly into the cord without any communication with the amniotic cavity. Moreover, any contribution of a fetoprotein from the amniotic fluid to the rise in maternal a fetoprotein concentration should be irrelevant as the concentration in fetal blood is more than 100 times that in amniotic fluid. '6 De Silva et al reported that 0-28 ml of red cells produced a secondary Rh immune response in all of their 14 volunteers'7; in our study the increase in maternal Rh (D) antibody concentration was clinically important when the volume of haemorrhage was greater than 1 ml. As the mean fetal packed cell volume at the first transfusion was 0-20 (range 0-08-0-31) the results were comparable. In some instances the rise in antibody titre was dramatic, and although the consequences were not important as far as the rate of fall in fetal packed cell volume was concerned, the course of the disease in a subsequent pregnancy will probably be affected.
These results also suggest that sampling of fetal blood in patients with Rh isoimmunisation should not be routinely done for blood grouping early in pregnancy. Chronic urticaria with angio-oedema controlled by warfarin J Berth-Jones, P E Hutchinson, A C B Wicks,
We report a case of severe recurrent angio-oedema that responded to warfarin. This was a chance observation and may have implications for the pathogenesis and treatment of chronic urticaria.
Case report The patient, a 42 year old man, presented in March 1977 with weekly episodes of severe angio-oedema, which were unresponsive to chlorpheniramine and trimeprazine prescribed by his general practitioner. He also had essential hypertension, familial combined hyperlipidaemia, and ischaemic heart disease, having suffered his first myocardial infarction in 1975.
Treatment with H1 receptor blocking antihistamines was continued for 18 months, during which time he suffered episodes of urticaria and angio-oedema virtually daily, at times with severe facial swelling necessitating admission to hospital. He was subsequently treated with the H2 antagonist cimetidine combined with HI antagonists, subcutaneous adrenaline, danazol, and systemic steroids. Only the steroids had any effect, and the urticaria eventually became stable when he took prednisolone 12 5 mg on alternate days. Numerous attempts to reduce this dose failed.
In February 1981 he had a further myocardial infarction, which was complicated by multiple pulmonary emboli. He was treated with intravenous heparin, prednisolone 40 mg to control his angiooedema, and subsequently oral warfarin. He remained completely free from urticaria throughout this admission and was discharged taking warfarin, prednisolone 12-5 mg on alternate days, cimetidine, and brompheniramine. The dose of steroid was gradually reduced to 2 mg on alternate days, and the antihistamines were withdrawn with no deterioration. In May that year warfarin was stopped and his angio-oedema returned. The warfarin was restarted and his angio-oedema again came under control. He subsequently reported that he had repeated this procedure with the same result. He continued to take warfarin alone for his urticaria until July 1983, when he was admitted to hospital for further investigation and, without being informed or his consent being obtained, was given placebo warfarin tablets. One week later he developed severe generalised angiooedema. Warfarin was restarted, and he subsequently had only occasional mild episodes of urticaria without angio-oedema. These episodes affected small areas of the arms, legs, and trunk; were transient, lasting less than two hours; and were usually associated with a fall in the international normalised ratio to below 2-5 (full anticoagulation (international normalised ratio > 2 5) was required for optimal benefit). He had two further small myocardial infarctions.
The following measurements were normal: routine haematological and biochemical variables; concentrations of Clq esterase inhibitor, factor XII, antinuclear factor, antithrombin III (by functional and immunological assay), and protein C (corrected for the effect of warfarin); fibrinolysis induced by factor XII; and results of challenges with oral aspirin, tartrazine, benzoic acid, and yeast.
